Merck Stock Forecast for 2022 - 2025 - 2030

Updated on 12/02/2022

Stock Rating
6
Price Target
$110.00
Consensus
Outperform
Upside
0.18%
Analysts
19
Stock Rating
6
Upside
0.18%
Analysts
19
Price Target
$110.00

Merck Stock Forecast and Price Target

The average price target of $110.00 for Merck's stock set by nineteen distinguished analysts in recent weeks would represent a potential upside of approximately 0.18% from the last closing price in December, 2022 if reached by the end of the year. This potential increase is based on a high estimate of $125.00 and a low estimate of $97.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.

$110.00

0.18% Upside

Outperform
Outperform

Merck Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Price has grown, increasing from $65.71 to $91.14 – a growth of 38.71%. The next year looks promising for Merck, with analysts predicting Fair Value of $110.22 – an increase of 20.93%. Over the next nine years, experts anticipate that Merck's Fair Value will grow at a rate of 25.91%.

2022 Fair Value Forecast
$110.22
2023 Fair Value Forecast
$109.61
2024 Fair Value Forecast
$125.51
2025 Fair Value Forecast
$138.23
2026 Fair Value Forecast
$147.46
2027 Fair Value Forecast
$162.30
2028 Fair Value Forecast
$173.81
2029 Fair Value Forecast
$139.59
2030 Fair Value Forecast
$114.76
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$178.74 $181.36 0.98%
LLY Stock Forecast Eli Lilly and Outperform 16
$370.33 $333.19 5.85%
ABBV Stock Forecast AbbVie Outperform 7
$161.63 $164.23 -1.94%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£112.00 £136.08 28.85%
DHR Stock Forecast Danaher Outperform 16
$274.54 $320.15 14.74%

Merck Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Revenue has grown, increasing from $42.29B to $48.70B – a growth of 15.16%. The next year looks promising for Merck, with analysts predicting Revenue of $57.19B – an increase of 17.43%. Over the next nine years, experts anticipate that Merck's Revenue will grow at a rate of 5.67%.

2022 Rev Forecast
$57.19B
2023 Rev Forecast
$55.63B
2024 Rev Forecast
$58.09B
2025 Rev Forecast
$61.50B
2026 Rev Forecast
$63.75B
2027 Rev Forecast
$65.57B
2028 Rev Forecast
$66.95B
2029 Rev Forecast
$57.16B
2030 Rev Forecast
$51.46B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$80.88 $79.05 2.50%
AMGN Stock Forecast Amgen Hold 7
$285.94 $246.51 -9.77%
GILD Stock Forecast Gilead Sciences Outperform 9
$87.90 $69.65 -7.85%

Merck Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Dividend per Share has grown by 35.42%, from $1.92 to $2.60. For the next year, analysts are expecting Dividend per Share to reach $2.85 – an increase of 9.62%. Over the next nine years, experts predict that Dividend per Share will grow by 23.08%.

2022 DPS Forecast
$2.85
2023 DPS Forecast
$3.01
2024 DPS Forecast
$3.27
2025 DPS Forecast
$3.48
2026 DPS Forecast
$3.60
2027 DPS Forecast
$4.04
2028 DPS Forecast
$4.29
2029 DPS Forecast
$3.20
2030 DPS Forecast
$3.20
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CSL Stock Forecast CSL Outperform 16
$298.66 $228.01 -28.44%
GE Stock Forecast General Electric Outperform 17
$85.26 $94.11 5.56%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$250.83 $272.08 8.04%

Merck Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Free Cash Flow has grown by 16.30%, rising from $8.31B to $9.66B. For next year, analysts predict Free Cash Flow of $15.51B, which would mean an increase of 60.52%. Over the next nine years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.

2022 FCF Forecast
$15.51B
2023 FCF Forecast
$16.98B
2024 FCF Forecast
$18.83B
2025 FCF Forecast
$18.99B
2026 FCF Forecast
$19.57B
2027 FCF Forecast
$20.04B
2028 FCF Forecast
$20.24B
2029 FCF Forecast
$18.90B
2030 FCF Forecast
$15.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GSK Stock Forecast GSK Outperform 16
£14.15 £16.08 14.13%
MMM Stock Forecast 3M Hold 16
$125.99 $147.79 1.20%
BAYN Stock Forecast Bayer Outperform 7
55.03€ 67.79€ 43.56%

Merck Net Income Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Net Income has grown from $6.22B to $13.05B – a 109.79% increase. Next year, analysts are expecting Net Income to reach $18.42B – an increase of 41.16%. Over the next nine years, the forecast is for Net Income to grow by 29.43%.

2022 NI Forecast
$18.42B
2023 NI Forecast
$18.11B
2024 NI Forecast
$20.63B
2025 NI Forecast
$22.38B
2026 NI Forecast
$23.48B
2027 NI Forecast
$25.38B
2028 NI Forecast
$26.54B
2029 NI Forecast
$20.81B
2030 NI Forecast
$16.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
A Stock Forecast Agilent Technologies Outperform 17
$156.12 $157.63 3.77%
BAS Stock Forecast BASF Outperform 11
47.86€ 78.27€ 14.92%
IDXX Stock Forecast IDEXX Laboratories Outperform 16
$439.17 $531.75 5.88%

Merck EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Merck's EBITDA has grown by 29.80%, rising from $14.62B to $18.98B. For next year, analysts predict EBITDA of $24.07B, which would mean an increase of 26.84%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to $18.25B.

2022 EBITDA Forecast
$24.07B
2023 EBITDA Forecast
$23.74B
2024 EBITDA Forecast
$26.32B
2025 EBITDA Forecast
$28.06B
2026 EBITDA Forecast
$29.25B
2027 EBITDA Forecast
$31.55B
2028 EBITDA Forecast
$30.36B
2029 EBITDA Forecast
$22.16B
2030 EBITDA Forecast
$18.25B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ILMN Stock Forecast Illumina Outperform 16
$220.86 $258.00 14.33%
ALC Stock Forecast Alcon Outperform 15
CHF65.48 CHF0.00 29.15%
4503 Stock Forecast Astellas Pharma Outperform 18
¥2.13k ¥0.00 12.83%

Merck EBIT Forecast for 2022 - 2025 - 2030

In the last three years, Merck's EBIT has grown, rising from $10.10B to $15.86B – a growth of 56.97%. In the next year, analysts believe that EBIT will reach $21.68B – an increase of 36.73%. For the next nine years, the forecast is for EBIT to grow by 23.04%.

2022 EBIT Forecast
$21.68B
2023 EBIT Forecast
$21.25B
2024 EBIT Forecast
$24.18B
2025 EBIT Forecast
$25.78B
2026 EBIT Forecast
$27.27B
2027 EBIT Forecast
$29.56B
2028 EBIT Forecast
$29.96B
2029 EBIT Forecast
$24.15B
2030 EBIT Forecast
$19.51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAX Stock Forecast Baxter International Outperform 17
$52.38 $65.40 22.18%
4523 Stock Forecast Eisai Hold 18
¥9.78k ¥0.00 -32.48%
HOLX Stock Forecast Hologic Outperform 8
$76.99 $77.25 -1.29%

Merck EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Merck's EPS has grown, increasing from $4.34 to $6.02 – a growth of 38.71%. The next year looks promising for Merck, with analysts predicting EPS of $7.28 – an increase of 20.93%. Over the next nine years, experts anticipate that Merck's EPS will grow at a rate of 25.91%.

2022 EPS Forecast
$7.28
2023 EPS Forecast
$7.24
2024 EPS Forecast
$8.29
2025 EPS Forecast
$9.13
2026 EPS Forecast
$9.74
2027 EPS Forecast
$10.72
2028 EPS Forecast
$11.48
2029 EPS Forecast
$9.22
2030 EPS Forecast
$7.58
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
INCY Stock Forecast Incyte Outperform 9
$80.68 $95.69 1.64%
FRE Stock Forecast Fresenius SE & Co. KGaA Outperform 18
26.51€ 50.04€ 24.48%
AKZA Stock Forecast Akzo Nobel N.V. Outperform 18
67.40€ 113.10€ 60.98%